Vertex Prices Telaprevir At $49,200 For Course Of Therapy
This article was originally published in The Pink Sheet Daily
Executive Summary
In addition to setting a premium price over that for Merck's competing boceprevir, Vertex also indicated it still plans to go it alone on U.S. commercialization despite Merck/Roche alliance.